Akcea Therapeutics, Inc. Deferred Revenue Recognized
Akcea Therapeutics, Inc. reported Deferred Revenue Recognized of $28.80 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2020-03-02
- Akcea Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-09-30 was $2.30M, a 66.18% decline year-over-year.
- Akcea Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-06-30 was $10.20M, a 19.05% decline year-over-year.
- Akcea Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-03-31 was $5.50M, a 67.84% decline year-over-year.
- Akcea Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2018-09-30 was $6.80M.
- Akcea Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2019 was $28.80M, a 31.75% decline from fiscal 2018.
- Akcea Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2018 was $42.20M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2019-12-31 | $28.80M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $2.30M 10-Q · filed 2019-11-06 | $18.00M 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | $10.20M 10-Q · filed 2019-08-07 | $15.70M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $5.50M 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $42.20M 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $6.80M 10-Q · filed 2019-11-06 | $36.50M 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $12.60M 10-Q · filed 2019-08-07 | $32.90M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $17.10M 10-Q · filed 2019-05-09 |